

P.E. 2/15/02



FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549



Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For 15 February, 2002

GlaxoSmithKline plc  
(Name of registrant)




GLAXO WELLCOME HOUSE, BERKELEY AVENUE,  
GREENFORD, MIDDLESEX UB6 0NN  
(Address of principal executive offices)

Indicated by check mark whether the registrant files or will file annual reports  
under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No



GlaxoSmithKline

15 February, 2002

Securities and Exchange Commission  
Judiciary Plaza  
450 Fifth Street, NW  
Washington, DC 20549  
USA

GlaxoSmithKline plc  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS  
Tel. +44 (0)20 8047 5000  
[www.gsk.com](http://www.gsk.com)

Dear Sirs

GlaxoSmithKline plc

On behalf of GlaxoSmithKline plc (the "Company"), I enclose herewith one manually executed and seven conformed copies of the Company's Report on Form 6-K for 15 February, 2002.

Any questions regarding these documents should be directed to the undersigned at 020 8966 8000.

Kindly stamp the enclosed copy of this letter and return it to me in the enclosed envelope.

Yours faithfully

VICTORIA LLEWELLYN  
Authorised Signatory for and  
on behalf of GlaxoSmithKline plc

encs.



GlaxoSmithKline

GlaxoSmithKline plc  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS  
Tel. +44 (0)20 8047 5000  
[www.gsk.com](http://www.gsk.com)

### Directors' Interests

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

14 February 2002                      The Administrators of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") notified GlaxoSmithKline plc on the 15 February 2002, that as a result of movement in the fund on the 14 February 2002, the number of Ordinary Share ADRs held by the fund had decreased from 18,579,139 to 18,447,407 at an average price of \$50.0500.

The Plan is a discretionary fund of which all employees or former employees of SmithKline Beecham plc and its subsidiaries are potential beneficiaries. One of the Company's directors, Dr J P Garnier is therefore, interested in the shares held in the fund from time to time in the same way as other employees or former employees of SmithKline Beecham plc and its subsidiaries.

S M Bicknell  
Company Secretary

15 February 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: 15 February, 2002

By:



VICTORIA LLEWELLYN  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc